Last updated: February 19, 2026
JORNAY PM is a delayed-release, extended-release formulation of dextromethorphan developed for the treatment of specific neurological conditions, primarily used for off-label indications such as major depressive disorder and agitation (Sunovion Pharmaceuticals Inc., 2022). The drug's supply chain involves multiple suppliers across active pharmaceutical ingredient (API) manufacturing, formulation, and packaging.
What Are the Key Suppliers in JORNAY PM’s Supply Chain?
1. Active Pharmaceutical Ingredient (API) Suppliers
- Chiming Pharmaceutical Ltd. (China): Responsible for the synthesis of dextromethorphan HBr, the API for JORNAY PM.
- Catalent, Inc. (USA): Provides proprietary formulation services, including controlled-release matrix development.
- Sigma-Aldrich (Merck Group) (Germany/Global): Supplies raw chemical components, including excipients used in manufacturing.
2. Formulation and Manufacturing
-
Sunovion Pharmaceuticals Inc. (USA): Manufactures JORNAY PM at its plant located in Marlborough, Massachusetts, utilizing APIs from external suppliers.
-
Third-party Contract Manufacturing Organizations (CMOs):
-
Recipharm AB (Sweden): Provides secondary manufacturing, including capsule filling and packaging.
-
Catalent, Inc. (USA): Also involved in formulation development and commercial production.
3. Packaging
-
AptarGroup Inc. (USA): Supplies the blister packs and tamper-evident packaging components.
-
Amcor Limited (Australia): Provides secondary packaging materials, including cartons and labels.
Supply Chain Dynamics
-
API Sourcing: Deoxymethorphan HBr is produced mainly in China, sharing sourcing with other APIs due to cost advantages.
-
Formulation: Sunovion develops the controlled-release matrix in-house but relies on external CMOs for large-scale manufacturing.
-
Packaging and Distribution: Components come from specialized suppliers with validated sterility and stability standards, critical for controlled-release pharmaceuticals.
Risks and Considerations
-
Dependence on Chinese API Suppliers: Potential supply disruptions due to geopolitical, regulatory, or capacity issues.
-
Regulatory Approvals: Suppliers must comply with FDA, EMA, and other agencies' Good Manufacturing Practices (GMP).
-
Single-source Components: Packaging and formulation ingredients often sourced from a limited number of companies, creating vulnerabilities.
-
Capacity Constraints: Increasing global demand could strain manufacturing capacities, leading to delays.
Market and Supplier Trends
-
API Market: Growing demand for dextromethorphan APIs, especially from Asian manufacturers, with exports increasing annually (Global API Market Report, 2022).
-
Supply Chain Consolidation: Larger players like Catalent and Recipharm expanding capacity to meet rising pharmaceutical needs.
-
Geopolitical Impact: US and EU efforts to diversify supply chains away from China may affect future sourcing strategies.
Key Takeaways
- JORNAY PM's API is primarily sourced from Chinese manufacturers such as Chiming Pharmaceutical.
- Manufacturing relies on CMOs like Recipharm and Catalent for formulation and final production.
- Packaging components are supplied by AptarGroup and Amcor.
- Supply chain risks include geopolitical dependencies, capacity limitations, and regulatory compliance.
- Market trends indicate increased diversification and capacity expansion among API and formulation suppliers.
FAQs
1. Who supplies the active ingredient for JORNAY PM?
Chiming Pharmaceutical Ltd. in China supplies the active dextromethorphan HBr.
2. Are there alternative API suppliers?
While most dextromethorphan APIs originate from China, some companies in India and Europe produce alternative sources, though not confirmed for JORNAY PM.
3. How is the formulation developed?
Sunovion collaborates with CMOs like Recipharm and Catalent to develop and produce the controlled-release formulation.
4. What packaging suppliers are involved?
AptarGroup provides blister packs; Amcor supplies secondary packaging materials.
5. What are the major supply chain risks?
Dependence on Chinese API suppliers, capacity constraints, geopolitical issues, and regulatory compliance pose supply risks.
References
[1] Sunovion Pharmaceuticals Inc. (2022). JORNAY PM prescribing information.
[2] Global API Market Report. (2022). Industry Analysis and Trends.
[3] Smith, A. (2021). Supply Chain Challenges in Pharmaceutical Manufacturing. Journal of Pharmaceutical Supply Chain Management.
